Fluoro-Neplanocin A

Fluoro-Neplanocin A

SCHEMBL9214745

Nc1ncnc2c1ncn2C1C(F)=C(CO)C(O)C1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHCY P23526 18/20 1.00
ADORA2B P29275 2/20 0.51
DPP4 P27487 1/20 0.51
MEN1 O00255 1/20 0.51
SLC28A1 O00337 1/20 0.51
MAP3K7 O43318 1/20 0.51
SLC28A2 O43868 1/20 0.51
GAPDH P04406 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
MAPK1 P28482 1/20 0.51
ADORA2A P29274 1/20 0.51
ADORA1 P30542 1/20 0.51
STAT6 P42226 1/20 0.51
PI4KA P42356 1/20 0.51
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PI4K2B Q8TCG2 1/20 0.51
DOT1L Q8TEK3 1/20 0.51
SLC29A1 Q99808 1/20 0.51
PI4K2A Q9BTU6 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoro-Neplanocin A SCHEMBL9215628 1.00 AHCY (1.00) AHCYADORA2BDPP4MEN1SLC28A1
Fluoro-Neplanocin A SCHEMBL9214735 1.00 AHCY (1.00) AHCYADORA2BDPP4MEN1SLC28A1
SCHEMBL15390405 0.92 AHCY (1.00) AHCYADORA2BDPP4ADORA3ADORA2A
SCHEMBL863387 0.90 AHCY (0.82) AHCY
SCHEMBL3793061 0.90 AHCY (0.82) AHCY
SCHEMBL863521 0.90 AHCY (1.00) AHCY
SCHEMBL1521121 0.90 AHCY (0.82) AHCY
SCHEMBL10051881 0.89 AHCY (0.84) AHCY
SCHEMBL9216846 0.85 AHCY (1.00) AHCYADORA2BDPP4MEN1SLC28A1
SCHEMBL9214869 0.85 AHCY (1.00) AHCYADORA2BDPP4MEN1SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0347852-B1 Novel neplanocin derivatives MERRELL DOW PHARMA (US) 1995-08-23 EP claimed
EP-0347852-A2 Novel neplanocin derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1989-12-27 EP claimed
EP-2841109-B1 PRODRUGS OF HYDROXYL-COMPRISING DRUGS ASCENDIS PHARMA AS (DK) 2026-04-15 EP disclosed
EP-3782649-B1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS ASCENDIS PHARMA AS (DK) 2025-05-14 EP disclosed
US-20230381323-A1 RELEASABLE CONJUGATES FISH & RICHARDSON PC 2023-11-30 US disclosed
US-11786599-B2 Releasable conjugates QUIAPEG PHARMACEUTICALS AB (SE) 2023-10-17 US disclosed
US-20230123784-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels ASCENDIS PHARMA A/S (DK) 2023-04-20 US disclosed
US-11559482-B2 Biodegradable polyethylene glycol based water-insoluble hydrogels ASCENDIS PHARMA A/S (DE) 2023-01-24 US disclosed
EP-4011396-A1 RELEASABLE CONJUGATES QuiaPEG Pharmaceuticals AB (SE) 2022-06-15 EP disclosed
US-9120760-B2 Fluoro-homoneplanocin A and nucleoside derivatives, method for the synthesis thereof, and the pharmaceutical compositions comprising the same as an active component for treatment of cancer EWHA University—Industry Collaboration Foundation (KR) 2015-09-01 US disclosed
US-9120760-B2 Fluoro-homoneplanocin A and nucleoside derivatives, method for the synthesis thereof, and the pharmaceutical compositions comprising the same as an active component for treatment of cancer EWHA University—Industry Collaboration Foundation (KR) 2015-09-01 US disclosed
US-20130310403-A1 Fluoro-homoneplanocin A and nucleoside derivatives, method for the synthesis thereof, and the pharmaceutical compositions comprising the same as an active component for treatment of cancer EWHA UNIVERSITY - INDUSTRY COLABORATION FOUNDATION (KR) 2013-11-21 US disclosed
EP-0347852-B1 Novel neplanocin derivatives MERRELL DOW PHARMA (US) 1995-08-23 EP disclosed
EP-0347852-A2 Novel neplanocin derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1989-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310403-A1 Fluoro-homoneplanocin A and nucleoside derivatives, method for the synthesis thereof, and the pharmaceutical compositions comprising the same as an active component for treatment of cancer NME1, NTPCR, ENTPD5 AHCY 828/4885ADORA2B 1666/4885DPP4 1005/4885
US-20230123784-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels PLG, PHYKPL, PLOD3 AHCY 412/4885ADORA2B 4314/4885DPP4 1529/4885
US-20230381323-A1 RELEASABLE CONJUGATES GUSB, ABCB11, UGT2B7 AHCY 1436/4885ADORA2B 228/4885DPP4 828/4885
US-11559482-B2 Biodegradable polyethylene glycol based water-insoluble hydrogels PLG, PHYKPL, PLOD3 AHCY 412/4885ADORA2B 4314/4885DPP4 1529/4885
US-11786599-B2 Releasable conjugates GUSB, ABCB11, UGT2B7 AHCY 1436/4885ADORA2B 228/4885DPP4 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.